{"name":"Zealand Pharma","slug":"zealand","ticker":"ZEAL","exchange":"NASDAQ / OMX Copenhagen","domain":"zealandpharma.com","description":"Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.","hq":"Copenhagen, Denmark","founded":1997,"employees":"~350","ceo":"Adam Steensberg","sector":"Obesity / Metabolic / Peptide Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":450000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2021-01-01","label":"Zegalogue first approved","drug":"Zegalogue","drugSlug":"dasiglucagon","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"dasiglucagon patent cliff ($0.0B at risk)","drug":"dasiglucagon","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dapiglutide 7.5 mg","genericName":"Dapiglutide 7.5 mg","slug":"dapiglutide-7-5-mg","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zegalogue","genericName":"DASIGLUCAGON","slug":"dasiglucagon","indication":"Hypoglycemia due to diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Dapiglutide 7.5 mg","genericName":"Dapiglutide 7.5 mg","slug":"dapiglutide-7-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zegalogue","genericName":"DASIGLUCAGON","slug":"dasiglucagon","phase":"marketed","mechanism":"Zegalogue works by stimulating the release of glucose from stored energy sources in the body.","indications":["Hypoglycemia due to diabetes mellitus"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Zealand Pharma Announces FDA Approval of Dasiglucagon for the Treatment of Hypoglycemia in Adults with Diabetes","summary":"The FDA has approved dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes.","drugName":"dasiglucagon","sentiment":"positive"},{"date":"2022-11-07","type":"earnings","headline":"Zealand Pharma Reports Third Quarter 2022 Financial Results","summary":"Zealand Pharma reported revenue of $13.4 million for the third quarter of 2022, a 25% increase from the same period in 2021.","drugName":"","sentiment":"neutral"},{"date":"2022-06-30","type":"deal","headline":"Zealand Pharma Announces Collaboration with Eli Lilly and Company to Develop Dasiglucagon for the Treatment of Obesity","summary":"Zealand Pharma has entered into a collaboration with Eli Lilly and Company to develop dasiglucagon for the treatment of obesity.","drugName":"dasiglucagon","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement - simplywall.st","headline":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBudEdnVG9KV0VHYTdWX3NwcFYyblBfM3BOVnJKeFo5c25hMW1FWmhFckNwbWN5a0I5cl9kdHRmN0d5QmVIbDBuakNPa3Vab1NnMmFvVHVBVWplLTJFZlZDYThla2pOdw?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Stock Price, Trades & News - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Stock Price, Trades & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9DaTVidkN6YV9OMVZNUFh6a0lBZDhLN0c1UWhTX3YxMUcxRGlkRlpHaDBNN1l5N0VsMGR3cnZQZnUyVnBwYUtSVXVybFBadGVOMXZ1N2NXdngzT3VF?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Stock News, Headlines & Updates - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Stock News, Headlines & Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBydGNiYjFzTXFBcnhEVkVsSERWa21kTm9GLVN2RDJqTUJGWTBIQVVEcUVJZ29xSlBfdnlMM3MtSkVmejdMX3hfVnB6aDhLM2JzM0RJY2xwLVlCY0JnSVNvRHF0UXdJN1VDdk5SYnZ4bFVwNVd5VkpN?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Cyclically Adjusted PS Ratio : (As of Apr. 03, 2026) - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Cyclically Adjusted PS Ratio : (As of Apr. 03, 2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE81UjBTR1Z4MDFJRGMzRWNQeVhCaTA1UFBCZUF6YXo0TlBjYnM0WV9BM0VRd3ZMcV9mSXUyZTZkUDFoT1RFeXNTNVRnN1hKUWVlQTVhS2lzZmlYVmNwaVE?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Competitors 2026 - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9zOFd5T2FlVlgzejlOeWZuRnZVVWZ4M0paTlZURHJ1LVpWanN1WWlwWC10S1dlMmZ5TFZuRWVObHI5TWRDejRLMWxqNmtYOTEyd1FQd3lucFZISDI4Tkhv?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Stock Holders - Institutional & Insider Ownership - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Stock Holders - Institutional & Insider Ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBqemRCZmtHdXl3TlI3cFQ2T2tZQWl1a2t5S1VQTklBeGU5cm12NDJLdXBlRW9GQktLd1haTjVHZ2kxYjBKc3ZmODNvNTdVZllON09V?oc=5","date":"2026-03-31","type":"pipeline","source":"Yahoo Finance UK","summary":"Zealand Pharma A/S (22Z.F) stock price, news, quote and history - Yahoo Finance UK","headline":"Zealand Pharma A/S (22Z.F) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMXVlaWlYTWJZbmlPTVgtLTY1QlVESzF2M0o3VHRJcFVvUnIzd0VLTDM4Q09YVXJqbDZvR2FUWno4R3Z3SmhvN2xCT284dUlpb1hvb2Q0dVhwZTI2XzVrVVhrUVdZdXJBVUZNVWdFVUVfNXdWNTlScnVYbVc3UWRjcjZnXzZ5bHBwMEE?oc=5","date":"2026-03-31","type":"pipeline","source":"Yahoo Finance UK","summary":"Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 - Yahoo Finance UK","headline":"Total number of shares and voting rights in Zealand Pharma as of March 31, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQdndTM0NoVmMxMkM4VGtiRGtzcUpNWXlPWGw0RXRucjg5T2lzMkxEdEI1Vl8yeVh5MTlRbnV2UEFrcGc3Vjduc2R6WkJicUxiOGVGZzVfWWhOc0lyTU5PM1htNnZMR0MzM3dHWkVSVEd5V3hMcXdWR3hiOGRJaWd2UXk2ZktDNGxiaG9seFJ1MGVsSWV3MjAwQ1NRMUZVNmk4OTc0ZFNXOVBEMFA3LXpYckR4ZDBpTnRIaDN6bHhVc2xCYjZTbjFOdi1abzYtS0tHUU1acmNNNnFkVEYzUS1rY0hvWDhIeWVtT0VPSEF0V2pheVFyOWM4cWQyeE5tZk1oODNjVHBEUl96Y2NqZFE?oc=5","date":"2026-03-25","type":"pipeline","source":"BioSpace","summary":"Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation - BioSpace","headline":"Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPVWNyUmFQUVBrdEdyYmZQSEtlZHVRZUtQRzYzUl9RVkVVRVp5LS1vQnludno5MG1tTEZNTWd5eGk4T000ZmplRUhQcGliMDVzaXRwSnpJNkI1S0FwQk0tbGJtR2s2bGhCWk5jTEdqRC12enRDTG1rM1hVT3o4WWpka3FZZnBLYXhNMmpidndmSXRmN1FPaXNFbGFsa0YxWjZ6dXV2ekZB?oc=5","date":"2026-03-25","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation As New Cambridge Research Hub Expands AI Drug Discovery - Yahoo Finance","headline":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation As New Cambridge Research Hub Expands AI Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOS09hQzQwQUNBTmFMeGpKZTU3eUp5VWZLV3dBR1V4cHdCMmJ0NldXczJIMjNDM0c2RXJYUTZWeG9IRFFoR0k1NUVQNmZvWVhsWUtwQzFBTUdFNmtXZTdRbjdIUmVSVjE2emx5WW12cXVwZGtfZmhxbjN5cTIzbDUtdE1uaUp1TDg?oc=5","date":"2026-02-23","type":"trial","source":"Yahoo Finance","summary":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Profit Swing And Positive ZP9830 Phase 1a Data - Yahoo Finance","headline":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Profit Swing And Positive ZP9830 Phase 1a Data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTHBnWTRGTDdNX2tRVWRmdnJJUTEtN0ZDenVNVjBOWUpIMDNJSmZEVU53OE41VzdiMzc5RkUtVElNczNxRFRDMTBDYXNwRjZUZjJQTDlrSjA3NkJQREluc1hreFR3bHJhbVotOFZUcEN0QmFCNWxYRDBldDdzRGlrRTJpWGk3ZjA?oc=5","date":"2026-01-24","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Prolonged Share Price Weakness - Yahoo Finance","headline":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Prolonged Share Price Weakness","sentiment":"neutral"}],"patents":[{"drugName":"dasiglucagon","drugSlug":"dasiglucagon","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Novo Nordisk","Eli Lilly and Company","Sanofi"],"therapeuticFocus":["Metabolic Disorders","Obesity"],"financials":null,"yahoo":null}